Diversigen a provider of comprehensive microbiome analysis services, has announced a strategic partnership with BioCore Co. Ltd., a bioanalytical contract research organization, based in Seoul, South Korea. BioCore has an established reputation for quality service and a customer base that extends throughout Asia. This partnership expands BioCore's portfolio, adding Diversigen's advanced microbiome/metagenomics analysis to BioCore's extensive laboratory service offerings, and facilitates Diversigen's entry into the rapidly growing Asian pharmaceutical market.
"BioCore offers the best in a strategic partner – deep domain expertise, a solid reputation, and an innovative approach to serving their customers," said Dr. Caroline Popper, CEO of Diversigen. "We look forward to helping BioCore and their customers gain competitive advantage through solutions designed to accelerate and transform discovery research, accelerate otherwise lengthy clinical trials, and capitalize on the diverse opportunities of the microbiome."
Mr. H.S. Choie, President and CEO of BioCore said, "Our partnership with Diversigen gives BioCore an opportunity to broaden our reach in the Korean pharmaceutical market and provide our customers with access to the leading scientists in the exploding field of microbiome research."